Bloodwork Before and After PCT: What to Test and Why
Bloodwork Before and After PCT: What to Test and Why
PCT bloodwork is the only objective way to measure how suppressed your hormones are before post-cycle therapy begins — and whether your body has genuinely recovered after it ends. Running a targeted lab panel before PCT starts establishes your suppression baseline. Retesting 4–6 weeks after PCT finishes tells you whether testosterone, LH, and FSH have returned to functional levels, or whether recovery is incomplete and further evaluation is needed.
PCT Bloodwork — 3 Things to Know Before You Read On
Before PCT — Establish a Suppression Baseline
Run PCT bloodwork before starting post-cycle therapy. Key markers: Total Testosterone, LH, FSH, Estradiol, CBC, lipid panel, and liver enzymes. This tells you how deep suppression actually is and gives you a concrete starting point for measuring recovery progress.
After PCT — Retest at 4–6 Weeks Post-PCT
Rising LH and FSH are the first signs the HPTA is recovering — often before total testosterone normalizes. Run your recovery panel 4–6 weeks after the last PCT drug dose, not during PCT. Drug-driven LH elevation does not reflect autonomous axis recovery.
Recovery on Paper — What Good Numbers Look Like
Testosterone trending toward your pre-cycle baseline, LH and FSH above mid-range, HDL-C rebounding, hematocrit normalizing, liver markers cleared. All of this is visible in PCT bloodwork — symptoms alone are not a reliable substitute for actual lab data.
What This Guide Covers
Covered in This Guide
- Which labs to run before PCT starts
- Which labs to retest after PCT ends
- Total Testosterone, LH, FSH, Estradiol interpretation
- CBC — hematocrit, hemoglobin, RBC
- Lipid panel — HDL, LDL, triglycerides
- Liver markers — ALT, AST, GGT
- How to interpret recovery results and trajectory
- Common PCT bloodwork mistakes and how to avoid them
Not Covered Here
- PCT drug protocols and dosing — see What Is PCT
- Timing of when to start PCT — see PCT Timing Guide
- How suppression occurs — see Testosterone Suppression
- Hormonal recovery mechanism — see Hormonal Recovery
- TRT protocol bloodwork — see TRT Bloodwork Guide
- Lab ordering services by country
This guide is part of both the PCT section and the Bloodwork & Health section of MuscleScience.org. For PCT protocol context, see the PCT Library. For broader lab interpretation guidance, see the Bloodwork & Health Hub. For pre-cycle baseline guidance, see Blood Tests Before Steroids.
Why PCT Bloodwork Matters — Symptoms Are Not Enough
Suppression after a steroid cycle is not uniform. A 16-week testosterone enanthate cycle at 500 mg per week will suppress the HPTA far more profoundly than a 6-week anavar-only cycle. The depth of suppression affects how long recovery takes, whether PCT drugs are working, and when it is safe to conclude that post-cycle therapy has done its job. PCT bloodwork is the only way to know where you actually stand.
Symptoms — low libido, fatigue, mood changes, poor morning erections — partially correlate with low testosterone, but they are unreliable as clinical indicators during recovery. Testosterone can be suppressed to 200 ng/dL in one person who feels relatively normal, while another at 280 ng/dL is severely symptomatic. Without PCT bloodwork, you cannot separate the pharmacological effect of the PCT drug itself from genuine axis recovery — because SERMs act on mood and libido pathways independently of whether LH and FSH are actually rising.
LH and FSH Are the Leading Recovery Indicators
Before testosterone itself recovers, the pituitary must resume secreting LH and FSH. These two gonadotropins are the upstream signal: LH drives Leydig cell testosterone production, FSH supports spermatogenesis. When LH and FSH are rising in post-cycle therapy bloodwork, it means the hypothalamic-pituitary axis is responding to reduced androgen feedback and beginning to re-engage. If LH and FSH remain suppressed three to four weeks into PCT, recovery is not progressing as expected — and that requires investigation, not optimism.
PCT drugs like clomiphene and tamoxifen work by blocking estrogen receptors at the pituitary and hypothalamus, removing the negative feedback brake and allowing LH and FSH to rise. PCT bloodwork lets you verify that this mechanism is functioning — and tells you when it has done enough. See Why Steroids Cause Testosterone Suppression for the HPTA mechanism and How Hormonal Recovery Works After Steroids for the full recovery timeline.
Lipids, Liver Markers, and Hematocrit Are Part of the Picture
Recovery of testosterone, LH, and FSH is the primary goal of PCT. But PCT bloodwork serves a broader health-monitoring function as well. Anabolic steroid use — particularly oral 17-alpha-alkylated compounds and injectable testosterone at supraphysiological doses — can significantly alter lipid profiles, raise liver enzymes, and increase red blood cell production. A complete PCT bloodwork panel captures all of these markers and gives you a clear picture of where cardiovascular and hepatic health stands as recovery progresses.
Running a comprehensive blood panel before a steroid cycle establishes your individual baseline. PCT bloodwork then measures the delta — how far each marker moved from that personal reference point, and how completely it has returned. Without a pre-cycle baseline, you are comparing against a population average rather than your own physiology.
On reference ranges: Standard lab reference ranges are population averages. Your personal pre-cycle baseline — established with bloodwork before you began using — is more informative than any printed range. Where possible, compare your post-PCT values against your own history, not just the lab’s normal range.
PCT Bloodwork Panel One — The Suppression Baseline
The first round of PCT bloodwork should be drawn after the cycle has ended and the compounds have cleared — but before you take any PCT drugs. Timing matters: if you run bloodwork while still using, androgens in circulation will suppress LH and FSH, and the panel will not reflect your actual post-cycle baseline. Run this first PCT bloodwork panel on the same day you plan to start post-cycle therapy, or within two to three days before. That window gives you accurate numbers without meaningful drift from clearance.
Total Testosterone, LH, and FSH
These three markers form the core of any PCT bloodwork panel. Total testosterone at this stage will typically be very low — often below 200 ng/dL after a suppressive cycle, sometimes below 100 ng/dL after prolonged or heavy use. LH and FSH will usually be undetectable or near zero, which is the expected result of HPTA suppression. Seeing low numbers here is not alarming — it confirms the mechanism. What matters is what happens to these markers over the course of PCT.
LH and FSH recovery precedes testosterone recovery in most cases. If your post-PCT bloodwork shows LH rising toward 3–5 IU/L and FSH moving in the same direction while testosterone is still low, that is a positive trajectory — the signaling axis is recovering and the Leydig cells are beginning to respond. If both remain at zero weeks after PCT ends, the recovery signal is absent and further evaluation is warranted.
Estradiol (E2)
Estradiol is often overlooked in PCT bloodwork, but it is clinically relevant both before and after PCT. At the start of post-cycle therapy, if aromatizable androgens are still partially cleared, estradiol may be elevated relative to the current testosterone level. This elevated E2-to-T ratio can worsen symptoms and suppress LH/FSH through estrogen-driven negative feedback — exactly the mechanism PCT drugs target. Knowing your estradiol level at the start of PCT helps you understand the hormonal environment the drugs are working in. See Estradiol Before Steroids for baseline context and interpretation guidance.
CBC — Hematocrit, Hemoglobin, and RBC
A complete blood count is a necessary part of PCT bloodwork, particularly if your cycle included injectable testosterone or any compound known to stimulate erythropoiesis. Testosterone increases red blood cell production by suppressing hepcidin and stimulating erythropoietin, which raises hematocrit and hemoglobin. At supraphysiological doses, hematocrit can reach 50–54% or higher — a level associated with increased blood viscosity and elevated cardiovascular risk. Knowing your hematocrit at the start of PCT tells you whether donation or other management is warranted before recovery is complete. The CBC and hematocrit guide covers reference ranges, donation thresholds, and interpretation in the context of androgen use.
Lipid Panel — HDL, LDL, and Triglycerides
Anabolic steroid use — particularly oral 17-alpha-alkylated compounds, but also injectable testosterone at supraphysiological doses — substantially alters lipid profiles. The most consistent finding in the research is a significant reduction in HDL-C. PCT bloodwork before post-cycle therapy starts gives you a lipid baseline that reflects end-of-cycle damage. PCT bloodwork after recovery shows how completely HDL-C has rebounded. In most users running injectable testosterone without oral compounds, HDL-C returns toward pre-cycle levels within 3–6 months of cessation. With orals — especially stanozolol, oxandrolone, or oxymetholone — recovery is slower and suppression is more severe. The lipid panel guide covers this in full detail.
Liver Markers — ALT, AST, and GGT
If your cycle included oral 17-alpha-alkylated steroids, liver enzyme elevation is expected. ALT and AST can rise significantly — sometimes to two, three, or five times the upper limit of normal. GGT is a more sensitive marker of ongoing hepatic stress. PCT bloodwork before starting post-cycle therapy captures the end-of-cycle hepatic state. If liver markers are significantly elevated, it is worth waiting for them to normalize before adding compounds with hepatic load. Liver markers typically return to normal within 6–12 weeks of cessation in most users without underlying pathology. The liver markers guide covers interpretation and typical recovery timelines. For kidney markers — creatinine, eGFR, and BUN — see the kidney markers guide.
| Marker | Why It Matters Before PCT | Expected Finding Post-Cycle |
|---|---|---|
| Total Testosterone | Confirms depth of HPTA suppression | Very low — often <200 ng/dL after heavy cycles |
| LH / FSH | Confirms pituitary signaling is suppressed | Undetectable or near zero |
| Estradiol (E2) | Sets context for E2:T ratio; guides PCT drug use | Variable — may be elevated relative to low T |
| Hematocrit / Hemoglobin | Flags erythrocytosis risk from androgenic stimulation | May be elevated; depends on cycle length and dose |
| HDL-C / LDL-C | Captures cardiovascular marker damage from cycle | HDL typically suppressed, especially with orals |
| ALT / AST / GGT | Assesses hepatic state; guides caution with PCT drugs | Elevated if oral 17-AA steroids were used |
PCT Bloodwork Panel Two — The Recovery Assessment
The second round of PCT bloodwork should be drawn 4–6 weeks after post-cycle therapy has ended — not while you are still taking PCT drugs. Running bloodwork during PCT gives you a drug-influenced snapshot rather than a true recovery assessment. Clomiphene, for example, raises LH and FSH pharmacologically while you are taking it; those elevated values do not reflect where the axis will sit once the drug clears. The relevant question is what the axis sustains on its own, without pharmacological support.
If 4–6 weeks post-PCT your total testosterone is returning toward a functional range, LH and FSH are detectable and above mid-range, and other markers are trending toward baseline, recovery is progressing as expected. If testosterone remains very low and LH/FSH are still suppressed, that is a sign the HPTA has not resumed autonomous function and further evaluation is warranted.
When LH and FSH Signal Recovery
In post-PCT bloodwork, LH and FSH are the most informative markers for assessing HPTA recovery. A recovering axis will show LH rising into the 3–8 IU/L range and FSH moving similarly. These rising values precede the testosterone rebound because the Leydig cells take time to upregulate steroidogenic enzymes after a period of gonadotropin deprivation. PCT bloodwork showing rising LH and FSH — even if testosterone is still below normal — is a positive signal and confirms the mechanism is working.
The opposite pattern — undetectable LH and FSH at the post-PCT retest — suggests one of several possibilities: PCT duration was insufficient, suppression was deeper than expected, or there is a pre-existing pituitary or hypothalamic issue that was masked during use. This finding warrants a conversation with an endocrinologist, not another round of self-managed PCT. See Why Steroids Cause Testosterone Suppression and How Hormonal Recovery Works After Steroids for the biological background.
Total Testosterone in Recovery
Post-PCT bloodwork showing total testosterone above 400 ng/dL is generally considered a functional recovery threshold for most men, though this is not a hard clinical cutoff. Returning to your personal pre-cycle baseline is a more meaningful target than any arbitrary number. Some men recover to 500–700 ng/dL within 8–12 weeks post-cycle; others take longer, particularly after longer cycles, heavier suppression, or older age. If total testosterone remains below 300 ng/dL at the post-PCT retest, repeat testing is appropriate before drawing conclusions — a single low value may reflect timing, illness, stress, or testing conditions.
Estradiol, Lipids, and Liver Markers Post-PCT
As testosterone recovers, estradiol will rise alongside it — aromatization scales with testosterone levels. A post-PCT E2 in the 20–35 pg/mL range with testosterone in the 400–600 ng/dL range represents a normal ratio for most men. Watch for disproportionately high estradiol relative to the recovering testosterone, which can occur if body fat is elevated or residual aromatization from the cycle period is still active.
By the time of the post-PCT retest, liver enzymes from oral steroid cycles should be trending toward normal in most users — though full normalization can take 8–12 weeks from cessation. HDL-C recovery is slower: injectable testosterone cycles typically allow HDL to rebound within 3–6 months; oral compound users may wait longer. Including a lipid panel and liver markers in your post-PCT bloodwork gives you confirmation that these markers are moving in the right direction, not just the hormonal markers.
Hematocrit post-PCT: With testosterone levels falling during and after PCT, erythropoietic stimulation decreases and hematocrit should gradually normalize. Post-PCT bloodwork showing hematocrit above 50% warrants continued monitoring and potentially therapeutic phlebotomy, especially if cardiovascular symptoms are present. See the hematocrit and hemoglobin guide for management guidance.
6 PCT Bloodwork Markers and What Each One Tells You
Not all markers in a PCT bloodwork panel carry equal weight at every stage of recovery. Here is what each marker specifically reveals — and how to think about it in the context of post-cycle therapy rather than general health screening.
Total Testosterone
The primary output of HPTA recovery. PCT bloodwork uses total testosterone to confirm that Leydig cells are responding to rising LH. It is the lagging indicator — LH and FSH rise first, testosterone follows. A single low post-PCT value does not confirm permanent suppression; context and trajectory matter more than any one data point. Compare against your pre-cycle baseline, not just the lab reference range.
LH and FSH
The leading indicators of HPTA axis recovery. In PCT bloodwork, rising LH and FSH confirm that the pituitary is resuming autonomous gonadotropin secretion. They precede testosterone recovery by days to weeks. If LH and FSH are rising, recovery is directionally correct even when testosterone is still below range. If both remain undetectable at the post-PCT retest, the signaling axis has not recovered — that is a clinically significant finding requiring follow-up.
Estradiol (E2)
Informs the context for PCT drug selection and estrogen-related symptoms. A high E2:T ratio at the start of PCT indicates that residual aromatizable androgens are still clearing. Post-PCT bloodwork uses E2 to confirm that estradiol has tracked appropriately with the testosterone rebound — not too low, which causes joint pain and mood issues, and not disproportionately high. Most men recover well within the 20–35 pg/mL range alongside normal testosterone.
Hematocrit and Hemoglobin
Critical safety markers in PCT bloodwork following testosterone use. Supraphysiological androgens stimulate red blood cell production; hematocrit can remain elevated for weeks after cessation. Values above 50–52% represent meaningful blood viscosity risk. Post-PCT bloodwork tracks normalization as androgenic stimulation falls. If hematocrit remains elevated at the post-PCT retest, therapeutic phlebotomy or continued monitoring is appropriate before declaring recovery complete.
HDL-C and LDL-C
The cardiovascular health markers most affected by AAS use. HDL-C suppression is the most consistent lipid finding in research on anabolic steroid users — documented in PCT bloodwork studies going back decades. HDL carries reverse cholesterol transport function; prolonged suppression has real cardiovascular implications. Post-PCT bloodwork tracks how quickly HDL rebounds, which depends heavily on whether oral 17-AA compounds were used and for how long. LDL and triglycerides typically recover faster than HDL.
ALT, AST, and GGT
Liver health markers relevant in PCT bloodwork when the cycle included oral 17-alpha-alkylated steroids. ALT is the most liver-specific marker; AST rises with both liver and muscle stress, so heavy training can elevate it independently of hepatic load. GGT is the most sensitive indicator of ongoing hepatic inflammation. For post-PCT bloodwork, ALT and GGT returning toward normal confirms the liver is clearing the hepatic stress of the cycle. Persistently elevated GGT warrants investigation beyond the cycle itself.
What Recovery Looks Like in PCT Bloodwork Results
Interpreting PCT bloodwork is not about whether each marker falls within the printed reference range on the lab report — it is about direction, trajectory, and comparison to your own history. Recovery is a process that unfolds over weeks to months, and a single time point provides limited information. Two or three sequential PCT bloodwork panels, taken at defined intervals, give you a trend rather than a snapshot.
The Trajectory Is More Important Than Any Single Number
If post-PCT bloodwork at 4 weeks shows total testosterone at 320 ng/dL with LH at 3.2 IU/L and FSH at 2.8 IU/L, that is a meaningfully different situation than total testosterone at 320 ng/dL with LH and FSH both below 0.5 IU/L. The first scenario shows a recovering axis: gonadotropins are rising, testosterone will follow. The second shows a stalled axis despite a similar testosterone level. PCT bloodwork that includes gonadotropins gives you this diagnostic clarity — testosterone alone does not.
A useful framework: if each sequential PCT bloodwork panel shows LH and FSH increasing or stable above the lower limit of normal, and total testosterone is trending upward, recovery is progressing. If three to four months post-cycle your PCT bloodwork still shows low testosterone with absent gonadotropins, that warrants an endocrinology referral rather than another round of self-managed PCT.
When to Repeat PCT Bloodwork
A minimum of two PCT bloodwork panels is recommended for any moderately suppressive cycle: one before PCT, one 4–6 weeks after PCT ends. A third panel at three months post-cycle is useful for anyone who had significantly elevated hematocrit, severely suppressed HDL-C, or markedly elevated liver markers — to confirm full normalization of those markers. For context on the full hormonal recovery timeline, see How Hormonal Recovery Works After Steroids.
Men who ran longer cycles, used particularly suppressive compounds such as nandrolone or trenbolone, or experienced deep suppression may benefit from monthly PCT bloodwork for the first three months post-cycle. The additional panels provide data points for the trend and help identify stalled recovery early.
Individual Variation in Recovery
PCT bloodwork results vary considerably between individuals. Age is a significant factor: testosterone recovery in men over 35 tends to be slower and may be less complete than in younger men. Prior cycle history matters too — the HPTA is resilient, but repeated long cycles without adequate recovery intervals can affect the speed and completeness of recovery. Genetic variation in hypothalamic sensitivity, pituitary reserve, and Leydig cell function also contributes to differences in PCT bloodwork outcomes between users running similar cycles. PCT bloodwork from other people’s reported results is not a reliable guide for your own recovery — your own sequential data is the only meaningful dataset.
5 PCT Bloodwork Mistakes That Distort the Picture
- Mistake
Testing During PCT Instead of After It
Running PCT bloodwork while still taking clomiphene or tamoxifen measures the pharmacological effect of the drug — elevated LH and FSH driven by estrogen receptor blockade — not genuine autonomous axis recovery. The relevant PCT bloodwork is drawn 4–6 weeks after the last PCT drug dose, when the drug has cleared and the axis must sustain itself without pharmacological support. Misreading drug-driven LH elevation as recovery leads to stopping PCT prematurely and missing the actual recovery picture.
- Mistake
Omitting LH and FSH from the Panel
Ordering only total testosterone in PCT bloodwork is the single most common panel error. Testosterone without LH and FSH provides no information about axis recovery — only about the current output. A man who never used steroids can have total testosterone of 350 ng/dL with normal LH and FSH. A man post-cycle can have the same 350 ng/dL with LH below 0.2 IU/L. Those two situations are completely different, and PCT bloodwork without gonadotropins cannot distinguish them.
- Mistake
No Pre-Cycle Baseline
Without a pre-cycle PCT bloodwork baseline, you have no personal reference point. The printed lab reference range reflects a population average, not your individual physiology. If your natural testosterone was 380 ng/dL and post-PCT bloodwork shows 410 ng/dL, recovery may be complete. If your natural testosterone was 680 ng/dL, the same 410 ng/dL represents incomplete recovery — but you would not know that without the baseline. See Blood Tests Before Steroids for what to run before your first cycle.
- Mistake
Ignoring Lipids and Hematocrit
Treating PCT bloodwork as a hormone-only panel misses the cardiovascular risk picture. HDL-C suppression from AAS use has real clinical consequences that persist well beyond the cycle itself. Elevated hematocrit carries blood viscosity risk regardless of how recovered testosterone appears. A complete PCT bloodwork panel that includes a lipid panel and CBC provides the full cardiovascular status picture. Skipping these markers because symptoms are absent defeats the purpose of objective monitoring.
- Mistake
Using a Single Post-PCT Panel to Declare Recovery Complete
One PCT bloodwork result is a data point, not a trend. A single panel showing testosterone at 450 ng/dL at 4 weeks post-PCT does not mean recovery is complete — it means testosterone was 450 ng/dL on that specific day. LH and FSH may still be suboptimal, lipids may not have rebounded, and hematocrit may still be elevated. A follow-up panel at 3 months post-cycle confirms sustained recovery across all markers rather than a single-point snapshot that may not hold over time.
External References
- Baldo-Enzi G, et al. Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids. Metabolism. 1990;39(2):203–8. pubmed.ncbi.nlm.nih.gov/2105436
- Palatini P, et al. Cardiovascular effects of anabolic steroids in weight-trained subjects. J Clin Pharmacol. 1996;36(12):1132–40. pubmed.ncbi.nlm.nih.gov/9013370
- Aribarg A, et al. Suppression of spermatogenesis by testosterone enanthate in Thai men. J Med Assoc Thai. 1996;79(10):624–9. pubmed.ncbi.nlm.nih.gov/8996996
- Mauss J, et al. Effect of long-term testosterone oenanthate administration on male reproductive function. Acta Endocrinol (Copenh). 1975;78(2):373–84. pubmed.ncbi.nlm.nih.gov/1172906
- Fink J, Bentzen K, Horie S. Management of hematocrit levels for testosterone replacement patients, a narrative review. Sex Med Rev. 2025;13(2):229–236. pubmed.ncbi.nlm.nih.gov/40126900
- Alizadeh Pahlavani H, Veisi A. Possible consequences of the abuse of anabolic steroids on different organs of athletes. Arch Physiol Biochem. 2025;131(3):393–409. pubmed.ncbi.nlm.nih.gov/39895536
PCT Bloodwork Is the Only Objective Measure of Recovery
Symptoms give you a rough sense of where your body is during recovery, but they cannot tell you whether LH and FSH are resuming, whether HDL-C is rebounding, or whether hematocrit has normalized. PCT bloodwork does all of that. A targeted panel before post-cycle therapy starts — and a follow-up 4–6 weeks after it ends — gives you the data needed to assess recovery with precision rather than guesswork.
The markers that matter most are LH and FSH as the upstream signals of HPTA recovery, total testosterone as the downstream output, estradiol as the ratio context, hematocrit as the cardiovascular safety check, and the lipid panel as the long-term cardiovascular record. Liver markers are relevant if oral compounds were used. Together, these six categories of PCT bloodwork form a complete recovery picture that no symptom checklist can replicate.
Run your pre-cycle baseline before you start. Run your suppression panel before PCT begins. Run your recovery panel 4–6 weeks after PCT ends. If the numbers are not where they should be, repeat testing — and if the axis shows no recovery three to four months post-cycle, see an endocrinologist with your PCT bloodwork records in hand.
- PCT Library — full hub for all post-cycle therapy guides
- What Is Post-Cycle Therapy — the complete PCT primer
- Why Steroids Cause Testosterone Suppression — the HPTA mechanism
- How Hormonal Recovery Works After Steroids — LH, FSH, and testosterone timelines
- When to Start PCT After a Steroid Cycle — ester clearance and timing
- Blood Tests Before Steroids — building your pre-cycle baseline
- Bloodwork & Health Hub — all lab marker guides
- TRT Bloodwork Guide — ongoing monitoring reference
- Lipid Panel Guide — HDL, LDL, and cardiovascular markers
- Start Here — site orientation and reading order
For Educational Purposes Only
This article discusses PCT bloodwork and laboratory monitoring for educational and harm-reduction purposes. It does not constitute medical advice and is not a substitute for consultation with a qualified physician or endocrinologist. The information provided reflects published research and is intended to support informed decision-making, not to encourage or facilitate the use of controlled substances.
MuscleScience.org does not sell any compounds, medications, or supplements. All author names are pseudonyms. Author photographs are stylized portraits, not images of real individuals. See our About page and Disclaimer for full disclosure on editorial policy and anonymity.
